Q32 Bio Statistics
Total Valuation
Q32 Bio has a market cap or net worth of $98.35 million. The enterprise value is $63.96 million.
Important Dates
The last earnings date was Tuesday, May 5, 2026, before market open.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Q32 Bio has 16.96 million shares outstanding. The number of shares has increased by 5.51% in one year.
| Current Share Class | 16.96M |
| Shares Outstanding | 16.96M |
| Shares Change (YoY) | +5.51% |
| Shares Change (QoQ) | +11.93% |
| Owned by Insiders (%) | 0.71% |
| Owned by Institutions (%) | 20.72% |
| Float | 9.69M |
Valuation Ratios
The trailing PE ratio is 2.24.
| PE Ratio | 2.24 |
| Forward PE | n/a |
| PS Ratio | 1.88 |
| Forward PS | n/a |
| PB Ratio | 1.74 |
| P/TBV Ratio | 2.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 1.92 |
| EV / Sales | 1.19 |
| EV / EBITDA | 2.94 |
| EV / EBIT | 2.99 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.36, with a Debt / Equity ratio of 0.29.
| Current Ratio | 5.36 |
| Quick Ratio | 4.81 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 0.58 |
| Debt / FCF | n/a |
| Interest Coverage | 21.41 |
Financial Efficiency
Return on equity (ROE) is 157.18% and return on invested capital (ROIC) is 35.80%.
| Return on Equity (ROE) | 157.18% |
| Return on Assets (ROA) | 18.75% |
| Return on Invested Capital (ROIC) | 35.80% |
| Return on Capital Employed (ROCE) | 40.39% |
| Weighted Average Cost of Capital (WACC) | -1.73% |
| Revenue Per Employee | $2.44M |
| Profits Per Employee | $1.51M |
| Employee Count | 22 |
| Asset Turnover | 0.75 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +249.40% in the last 52 weeks. The beta is -1.27, so Q32 Bio's price volatility has been lower than the market average.
| Beta (5Y) | -1.27 |
| 52-Week Price Change | +249.40% |
| 50-Day Moving Average | 5.99 |
| 200-Day Moving Average | 3.76 |
| Relative Strength Index (RSI) | 50.61 |
| Average Volume (20 Days) | 268,741 |
Short Selling Information
The latest short interest is 652,815, so 3.85% of the outstanding shares have been sold short.
| Short Interest | 652,815 |
| Short Previous Month | 382,350 |
| Short % of Shares Out | 3.85% |
| Short % of Float | 6.74% |
| Short Ratio (days to cover) | 1.79 |
Income Statement
In the last 12 months, Q32 Bio had revenue of $53.74 million and earned $33.24 million in profits. Earnings per share was $2.59.
| Revenue | 53.74M |
| Gross Profit | 38.49M |
| Operating Income | 21.41M |
| Pretax Income | 33.24M |
| Net Income | 33.24M |
| EBITDA | 21.77M |
| EBIT | 21.41M |
| Earnings Per Share (EPS) | $2.59 |
Full Income StatementBalance Sheet
The company has $50.75 million in cash and $13.65 million in debt, with a net cash position of $37.11 million or $2.19 per share.
| Cash & Cash Equivalents | 50.75M |
| Total Debt | 13.65M |
| Net Cash | 37.11M |
| Net Cash Per Share | $2.19 |
| Equity (Book Value) | 46.31M |
| Book Value Per Share | 3.17 |
| Working Capital | 46.53M |
Full Balance SheetCash Flow
| Operating Cash Flow | -27.40M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 362,000 |
| Net Borrowing | -4.69M |
| Free Cash Flow | -27.40M |
| FCF Per Share | -$1.62 |
Full Cash Flow StatementMargins
Gross margin is 71.62%, with operating and profit margins of 39.84% and 61.86%.
| Gross Margin | 71.62% |
| Operating Margin | 39.84% |
| Pretax Margin | 61.86% |
| Profit Margin | 61.86% |
| EBITDA Margin | 40.51% |
| EBIT Margin | 39.84% |
| FCF Margin | n/a |
Dividends & Yields
Q32 Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.51% |
| Shareholder Yield | -5.51% |
| Earnings Yield | 32.89% |
| FCF Yield | -27.12% |
Analyst Forecast
The average price target for Q32 Bio is $14.33, which is 147.07% higher than the current price. The consensus rating is "Buy".
| Price Target | $14.33 |
| Price Target Difference | 147.07% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Q32 Bio has an Altman Z-Score of -0.61 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.61 |
| Piotroski F-Score | 4 |
